Multi-Centre European Experience with Intragastric Balloon in Overweight Populations: 13 Years of Experience
- Alfredo GencoAffiliated withLaparoscopic Surgical Department, Medical School, “La Sapienza” University
- , Gontrand López-NavaAffiliated withDepartment of Digestive and Endoscopy, Madrid Sanchinarro University Hospital
- , Christian WahlenAffiliated withCentre Hospitalier Chrétien
- , Roberta MaselliAffiliated withLaparoscopic Surgical Department, Medical School, “La Sapienza” University
- , Massimiliano CiprianoAffiliated withLaparoscopic Surgical Department, Medical School, “La Sapienza” University
- , Maria Mara Arenas SanchezAffiliated withDepartment of Digestive and Endoscopy, Madrid Sanchinarro University Hospital
- , Chantal JacobsAffiliated withCentre Hospitalier Chrétien
- , Michele LorenzoAffiliated withASL NA 3 SUD, U.O.M.L Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The request to lose weight is expanding not only in obese and morbidly obese patients but also in overweight patients affected by co-morbidities as diabetes and hypertension and who do not tolerate diet regimen or lifestyle changes. The aim of this study is a multicenter evaluation of outcomes of intragastric balloon in overweight patients.
Patients (BMI 27–30 kg/m2) treated with a BioEnterics Intragastric Balloon (BIB) between 1996 and 2010 were extracted from the database of the participating centres in Rome (Italy), Liège (Belgium) and Madrid (Spain). Primary endpoints were the efficacy and safety at 6 and 42 months from balloon positioning. Secondary endpoints included resolution of co-morbidities.
A total of 261 patients were included in this study. The most common indication for balloon placement was a psychological disorder (54 %). Mean body mass index (BMI) fell from 28.6 ± 0.4 at baseline to 25.4 ± 2.6 kg/m2 at 6 months and to 27.0 ± 3.1 kg/m2 at 3 years from BIB removal. The mean %EWL was 55.6 % at 6 months and 29.1 % at 3 years. Forty-seven patients (18 %) had complications associated with placement of the intragastric balloon (leak = 28, intolerance = 14, duodenal ulcer = 2, gastritis = 1, oesophagitis = 1, duodenal polyps = 1). The rate of patients with hypertension decreased from 29 % at baseline to 16 % at 3 years. Diabetes decreased from 15 to 10 %, dyslipidaemia decreased from 20 to 18 %, hypercholesterolaemia decreased from 32 to 21 % and osteoarthropathy decreased from 25 to 13 %.
The intragastric balloon is safe and effective in overweight patients, helping to reduce progression to obesity and decreasing the prevalence of a number of important co-morbidities.
KeywordsIntragastric balloon Obesity Overweight BMI %EWL Co-morbidities
- Multi-Centre European Experience with Intragastric Balloon in Overweight Populations: 13 Years of Experience
Volume 23, Issue 4 , pp 515-521
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Intragastric balloon
- Industry Sectors
- Author Affiliations
- 1. Laparoscopic Surgical Department, Medical School, “La Sapienza” University, Rome, Italy
- 2. Department of Digestive and Endoscopy, Madrid Sanchinarro University Hospital, Madrid, Spain
- 3. Centre Hospitalier Chrétien, Liège, Belgium
- 4. ASL NA 3 SUD, U.O.M.L, Via Maresca 54, 80058 Torre Annunziata, Naples, Italy